
Active Fibroblast Growth Factor 19 (FGF19)

Catalog#:PEH12877

概述（Summary）

纯度（Purity）	Greater than 90% as determined by reducing SDS-PAGE.
内毒素（Endotoxin level）	Please contact with the lab for this information
蛋白构建（Construction）	【Leu25-Lys216】
Accession #	O95750
表达宿主（Host）	E.coli
种属（Species）	Homo sapiens (Human)
预测分子量（Predicted MW）	25.1 kDa
制剂（Form）	Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
运输方式（Shipping）	The product is shipped with ice bag. Upon receipt, store it immediately at the temperature listed below.
稳定性&储存（Stability &Storage）	12 months at -20°C to -80°C in lyophilized state.6 months at -20°C to -80°C under sterile conditions after reconstitution.7-10 days at 2°C to 8°C under sterile conditions after reconstitution.Please minimize freeze-thaw cycles.
复溶（Reconstitution）	Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
背景介绍（References）	Involved in the suppression of bile acid biosynthesis through down-regulation of CYP7A1 expression, following positive regulation of the JNK and ERK1/2 cascades. Stimulates glucose uptake in adipocytes. Activity requires the presence of KLB and FGFR4.

电泳图（SDS-PAGE image）



Greater than 90% as determined by reducing SDS-PAGE.

活性图（Bioactivity image）




Figure 1. The binding activity of recombinant human FGF19 and recombinant human FGFR1

Fibroblast Growth Factor 19 (FGF19) is a member of the fibroblast growth factor (FGF) family. FGFs are heparin-binding growth factors with a core 120 amino acid (aa) FGF domain that allows for a common tertiary structure. In general, FGFs are expressed during embryonic development and in restricted adult tissues.Human FGF-19 cDNA predicts a 251 aa precursor protein with a 22 aa signal peptide and a 229 aa secreted mature protein with no potential N-linked glycosylation sites. FGF19-FGFR1 is one of paired transcripts mediating the dialogues between extraembryonic membrane and endometrium. Thus a functional binding ELISA assay was conducted to detect the interaction of recombinant human FGF19 and recombinant human FGFR1. Briefly, FGF19 were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100 µl were then transferred to FGFR1-coated microtiter wells and incubated for 2h at 37℃. Wells were washed with PBST and incubated for 1h with anti-FGF19 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50 µL stop solution to the wells and read at 450 nm immediately. The binding activity of recombinant human FGF19 and recombinant human FGFR1 was shown in Figure 1, the EC50 for this effect is 3.83 ug/mL.

注意事项（Note）

For Research Use Only , Not for Diagnostic Use.